Sab Biotherapeutics, INC. (SABS) — SEC Filings
Latest SEC filings for Sab Biotherapeutics, INC.. Recent 8-K filing on Apr 22, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Sab Biotherapeutics, INC. on SEC EDGAR
Overview
Sab Biotherapeutics, INC. (SABS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 22, 2026: SAB Biotherapeutics, Inc. filed an 8-K on April 22, 2026, primarily for Regulation FD Disclosure and Financial Statements/Exhibits. The filing includes various documents such as an iXBRL 8-K, exhibits (EX-99.1, EX-99.2), graphics, and a PDF courtesy copy of EX-99.2. It also contains XBRL data files.
Sentiment Summary
Across 2 filings, the sentiment breakdown is: 2 neutral. The dominant filing sentiment for Sab Biotherapeutics, INC. is neutral.
Filing Type Overview
Sab Biotherapeutics, INC. (SABS) has filed 1 4, 1 8-K with the SEC between Mar 2026 to Apr 2026.
Recent Filings (2)
-
SAB Biotherapeutics Files 8-K with Exhibits
— 8-K · Apr 22, 2026 Risk: low
SAB Biotherapeutics, Inc. filed an 8-K on April 22, 2026, primarily for Regulation FD Disclosure and Financial Statements/Exhibits. The filing includes various -
SAB Biotherapeutics: Insider Ownership Change Filed by Kropotova
— 4 · Mar 25, 2026
This Form 4 filing, dated March 25, 2026, indicates a change in beneficial ownership for SAB Biotherapeutics, Inc. (SABT) involving Alexandra Kropotova. While t
Risk Profile
Risk Assessment: Of SABS's 1 recent filings, 0 were flagged as high-risk, 0 as medium-risk, and 1 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Top Tags
disclosure (1) · exhibits (1) · filing (1) · insider-activity (1) · ownership-change (1) · form-4 (1)
Key Numbers
- SEC Accession Number: 0001193125-26-168569 — Unique identifier for the filing
Frequently Asked Questions
What are the latest SEC filings for Sab Biotherapeutics, INC. (SABS)?
Sab Biotherapeutics, INC. has 2 recent SEC filings from Mar 2026 to Apr 2026, including 1 4, 1 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SABS filings?
Across 2 filings, the sentiment breakdown is: 2 neutral. The dominant sentiment is neutral.
Where can I find Sab Biotherapeutics, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sab Biotherapeutics, INC. (SABS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sab Biotherapeutics, INC.?
Financial highlights for Sab Biotherapeutics, INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for SABS?
Investment thesis data for SABS will be available once enriched filings are processed.
Who are the key executives at Sab Biotherapeutics, INC.?
Executive information for Sab Biotherapeutics, INC. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Sab Biotherapeutics, INC. stock?
Of SABS's 1 assessed filings, 0 were flagged high-risk, 0 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Sab Biotherapeutics, INC.?
Forward guidance and predictions for Sab Biotherapeutics, INC. are extracted from SEC filings as they are enriched.